Nandu Gourineni, MD
Interventional Cardiology · Lakeway, TXNPI 1033231220
Payments from drug & device makers
Across 305 payments — averaging $86.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$10K
- Boston Scientific$6K
- Medtronic$4K
- Cardiovascular Systems Inc.$1K
- Abbott$1K
- Abiomed$629
- plus $3K from 27 others
What the payments were for
- Consulting fees$6,04023%
- Grants$1,1234%
- Travel & lodging$10,91642%
- Food & beverage$8,18131%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 48 | $10,173 |
| Boston Scientific | 49 | $5,701 |
| Medtronic(2 entities) | 31 | $4,141 |
| Cardiovascular Systems Inc. | 12 | $1,275 |
| Abbott | 29 | $1,235 |
| Abiomed | 5 | $629 |
| Amgen | 26 | $619 |
| Johnson & Johnson | 25 | $474 |
| Philips North America LLC | 10 | $303 |
| Inari Medical, Inc. | 4 | $290 |
| AstraZeneca | 12 | $199 |
| Pfizer | 9 | $162 |
| Novartis | 7 | $120 |
| Teleflex LLC | 4 | $116 |
| Terumo Medical Corporation | 3 | $113 |
| Asahi Intecc USA, Inc. | 1 | $106 |
| E.r. Squibb & Sons, L.L.C. | 6 | $105 |
| Boehringer Ingelheim | 4 | $78 |
| Stryker | 1 | $74 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $65 |
| Novo Nordisk | 2 | $43 |
| W. L. Gore & Associates, Inc. | 1 | $34 |
| Irhythm Technologies, Inc. | 1 | $33 |
| Heartflow, Inc. | 1 | $29 |
| Cardiva Medical, Inc. | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Lantheus Medical Imaging, Inc. | 1 | $21 |
| Penumbra, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Getinge USA Sales, LLC | 1 | $14 |
| Chiesi USA, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$5,755
- Edwards SAPIEN 3 Transcatheter Heart Valve$3,172
- VersaCross Access Solution$2,483
- CoreValve Evolut$1,896
- GENERAL VASCULAR ACCESS$1,261
- 3F$1,123
- Peripheral Orbital Atherectomy System$906
- Impella$629
- CARDIOMEMS$518
- COREVALVE EVOLUT R$509
- WATCHMAN Access System$496
- CROSSBOSS$375
- Repatha$252
- Diamondback Peripheral$158
- FLOWTRIEVER CATHETER, S$130
- CT THROMBECTOMY SYSTEM KIT$130
- (6575) Coronary Undivided$115
- AVVIGO Guidance System$109
- ASAHI PTCA Guide Wire$106
How this compares
$26,284 in reported general payments places this provider in the 70th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 219 | $255,074 |
| EntrestoSacubitril/Valsartan | 59 | $58,358 |
| BrilintaTicagrelor | 62 | $45,495 |
| XareltoRivaroxaban | 23 | $30,936 |
| Repatha SureclickEvolocumab | 30 | $30,574 |
| Ranolazine ErRanolazine | 50 | $4,395 |
| Metoprolol Succinate | 365 | $4,147 |
| Atorvastatin Calcium | 303 | $2,453 |
| ClopidogrelClopidogrel Bisulfate | 213 | $1,833 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 72 | $1,646 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 125 | $1,388 |
| Rosuvastatin Calcium | 105 | $1,044 |
| Ezetimibe | 65 | $879 |
| Furosemide | 132 | $680 |
| Metoprolol Tartrate | 91 | $657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $162 | $255,074219 claims |
| NovartisEntresto | $120 | $58,35859 claims |
| AstraZenecaBrilinta | $199 | $45,49562 claims |
| Johnson & JohnsonXarelto | $474 | $30,93623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Lakeway
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
- Jeffrey CarrTyler$2.7M
- M Asad KarimMcKinney$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.